Cytidine (Cyd)

Cytidine is a pyrimidine nucleoside consisting of a cytosine base attached to a ribose sugar via a beta-N1-glycosidic bond (PubChem CID 6175). It is a fundamental building block for ribonucleic acid (RNA) and serves as a precursor for the synthesis of cytidine nucleotides such as CMP, CDP, and CTP. CTP is particularly important as a cofactor in the biosynthesis of membrane phospholipids, including phosphatidylcholine and phosphatidylethanolamine (NCBI MeSH). In the cellular salvage pathway, cytidine is phosphorylated by uridine-cytidine kinases (UCK1 and UCK2) to enter the nucleotide pool (UniProt P52630). While cytidine itself is a naturally occurring metabolite and not a protein target, its metabolic pathways are of significant pharmacological interest. Many therapeutic agents are synthetic analogs of cytidine, designed to interfere with nucleic acid synthesis or epigenetic regulation. For example, the drugs azacitidine and decitabine act as hypomethylating agents by inhibiting DNA methyltransferases after being incorporated into DNA (DrugBank DB00149). Other analogs like gemcitabine and cytarabine are used in chemotherapy to induce cell death by inhibiting DNA polymerase or causing chain termination. The efficacy of these drugs is often limited by the activity of cytidine deaminase, an enzyme that rapidly catabolizes both natural cytidine and its analogs into inactive uracil derivatives. Consequently, understanding cytidine metabolism is crucial for optimizing the delivery and performance of nucleoside-based therapies.

Other names

1-beta-D-RibofuranosylcytosineCytosine ribosideCytosine-1-beta-D-ribofuranosideC

Cytidine analogs function as antimetabolites that are intracellularly phosphorylated to active triphosphate forms; these metabolites then inhibit DNA methyltransferases, leading to DNA hypomethylation, or incorporate into DNA and RNA strands to induce chain termination and apoptosis.